加载中
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
常规交易时段
US$4.94
−US$0.01 · -0.20%
盘中时间采用ET。市场数据可能有所延迟。
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
日内区间
当前US$4.94
52周区间
当前US$4.94
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
84
深度低估
情绪
59
多空交织
风险
58
风险偏高
动量
60
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
日内区间
当前US$4.94
52周区间
当前US$4.94
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 794.58万 USD | 355.41万 USD | 600.22万 USD | — | — |
| 销货成本 | 2.74万 USD | 1186.57万 USD | 550.15万 USD | 441.25万 USD | — |
| 毛利 | 791.84万 USD | −831.16万 USD | 50.07万 USD | −441.25万 USD | — |
| 研究与开发 | 1673.45万 USD | 1189.07万 USD | 604.47万 USD | 493.75万 USD | 254.21万 USD |
| 销售、一般及管理费用 | 1144.95万 USD | 888.58万 USD | 783.35万 USD | 484.71万 USD | 231.2万 USD |
| 营业费用 | 2818.4万 USD | 893.81万 USD | 840.4万 USD | 539.94万 USD | 487.03万 USD |
| 折旧和摊销 | 2.74万 USD | 2.74万 USD | 2.74万 USD | 2.74万 USD | 1.61万 USD |
| 营业利润 | −2026.56万 USD | −1724.97万 USD | −790.33万 USD | −981.19万 USD | −487.03万 USD |
| 净利润 | −2122.61万 USD | −1488.08万 USD | −798.78万 USD | −1224.48万 USD | −489.18万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI274.11万0.00%2.3万亿 USD0.03%US$381.79-0.04%
Vanguard Extended Market ETFVXF105.1万0.00%954亿 USD0.05%US$234.31-0.30%
Dimensional - US Small Cap ETFDFAS45.94万0.00%338.69亿 USD0.31%US$78.46+0.14%
iShares Micro-Cap ETFIWC30.91万0.02%13.17亿 USD0.60%US$182.41-0.32%
U.S. Micro Cap Portfolio ETFDFMC19.22万0.00%75.58亿 USD0.43%US$57.79-0.04%
Avantis U.S. Small Cap Equity ETFAVSC5.55万—30.82亿 USD0.25%US$70.18+0.29%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4.14万0.00%61.81亿 USD0.26%US$68.3771+0.14%
Dimensional - US Core Equity 2 ETFDFAC2.73万0.00%885.96亿 USD0.21%US$45.375+0.10%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
